BKM120 belongs to a group if medicines called (phosphatidylinositol 3'-kinase) P13K-inhibitors. BKM120 blocks the activity of the P13K protein which belongs to the P13K pathway in tumor cells. This pathway is well known to be involved in tumor cell multiplication and survival. Many cancers, such as non-small cell lung cancer, are known to have an activated P13K pathway. P13K pathway activation depends on changes in multiple molecules. The changes in P13KCA (a gene coding for P13K protein) and a molecule called PTEN (phosphatase and tensin homolog) are responsible for keeping the P13K pathway on or active. This continuous P13K pathway activation contributes to the growth of tumors.
The goal of this study is to find out if BKM120 has any effect in patients with non-small cell lung cancer with an activated P13K pathway. The study will be conducted n a two-stage format.
See Clinical Trials. gov listing for Eligibility criteria